

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

ANNOUNCEMENT IN RELATION TO THE RECEIPT OF “NOTICE REGARDING FIRST FEEDBACK COMMENTS ON THE REVIEW BY THE CHINA SECURITIES AND REGULATORY COMMISSION OF ADMINISTRATIVE PERMISSION ITEMS” IN RELATION TO THE APPLICATION CONCERNING THE PROPOSED A SHARE ISSUE OF THE COMPANY

Reference is made to the announcement (the “**Announcement**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) dated 19 July 2021 in relation to the Acceptance Notice of the Application for Administrative Permission (《中國證監會行政許可申請受理單》) (No.: 211868) issued by the China Securities Regulatory Commission (the “**CSRC**”) on 19 July 2021 concerning the formal acceptance by the CSRC of application materials concerning the Proposed A Shares Issue. Unless otherwise defined, the capitalised terms used in this announcement shall have the meanings in the Announcement.

On 30 July 2021, the Company received the Notice regarding China Securities Regulatory Commission's First Feedback Comments on the Review of Administrative Permission Items (No. 211868) (the “**Notice**”) issued by the CSRC, setting out the initial feedback comments from the CSRC following its review of the Application concerning the Proposed A Shares Issue. Pursuant to the Notice, the Company is required to respond to the comments set out in the Notice by way of public disclosure and submission of written explanations to the relevant department of the CSRC within the prescribed period of 30 days (or such longer period upon application of an extension, if required).

Accordingly, the Company and relevant intermediate agencies will prepare the relevant materials in a timely manner and make submission to the CSRC and public disclosure of written explanations in response to the comments set out in the Notice within the prescribed period.

The Proposed A shares Issue remains subject to the approval of the CSRC. The Company will make further announcements with respect to the progress of the approval of the CSRC in accordance with the applicable rules and requirements in the PRC as and when appropriate.

The completion of the Proposed A Shares Issue is subject to the satisfaction of certain conditions, including but not limited to the obtaining of the approval from the CSRC. Accordingly, the Proposed A Shares Issue may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares, and are recommended to consult their professional adviser if they are in any doubt about their position and as to actions they should take.

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited

Zhang Daiming

Chairman

2 August 2021, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Zhang Daiming (*Chairman*)
Mr. Du Deping
Mr. He Tongqing

Independent Non-executive Directors:

Mr. Pan Guangcheng
Mr. Zhu Jianwei
Mr. Lo Wah Wai

Non-executive Directors:

Mr. Cong Kechun
Mr. Xu Lie

As at the date of this announcement, the directors of HHC include Mr. Fan Jun, Mr. Ding Zhenbo, Mr. Sun Youmin, Mr. Zhang Yuming, and Mr. Lou Hongxiang.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement other than those relating to HHC and parties acting in concert with it, and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.

The directors of HHC jointly and severally accept full responsibility for the accuracy of the information contained in this announcement other than those relating to the Company, and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.